The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
LettersFull Access

Recovery and Realism

In Reply: Dr. Aquila and colleagues correctly point out that people with serious mental illness can get better, that hope is an important part of recovery, and that newer medications have some demonstrable advantages. However, this is not true for all clients, and my editorial argued for a balanced perspective, consistent with the available scientific evidence.

I was recently at a conference on atypical antipsychotics at which one member of the audience expressed concern that if we claim these medications are transformingly effective, funding agencies may argue that fewer resources are needed for rehabilitation services or for supported housing. Some payers have already argued that the dramatically reduced availability of acute inpatient care for mental illness is justifiable because of the availability of these medications. I do not feel the evidence justifies such reductions.

Neither an editorial nor a letter is the place for a review of scientific evidence. However, I believe the literature does suggest that our progress has been incremental and that while some side effects are reduced, others are increased. Realism should not be seen as the enemy of hope, but rather as the backdrop that highlights its overwhelming importance.

Dr. Rosenheck is director of the Veterans Affairs Northeast Program Evaluation Center and professor of psychiatry and public health at Yale School of Medicine in New Haven, Connecticut.